Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer.
Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer.
复制标题
DOI：
10.1016/j.ygyno.2022.10.012
复制
发表时间：
2022-12
影响因子：
4.7
通讯作者：
Makker, Vicky
中科院分区：
文献类型：
--
作者：
Rubinstein, Maria;Shen, Sherry;Monk, Bradley J.;Tan, David S. P.;Nogueira-Rodrigues, Angelica;Aoki, Daisuke;Sehouli, Jalid;Makker, Vicky
子宫内膜癌的发病率和死亡率在所有族裔群体中都在上升。卡铂加紫杉醇是晚期/复发性疾病的既定一线治疗;然而，传统细胞毒性化疗的后续治疗具有挑战性。子宫内膜癌的分子特征为了解致癌的生物学驱动因素提供了重要的见解，这使得开发新的精确免疫疗法和靶向疗法成为可能，包括pembrolizumab，dostarlimab和lenvatinib。直到最近，由于缺乏其他可用的治疗选择，通常在复发时考虑铂再激发;然而，子宫内膜癌的“铂敏感性”是主观的，主要基于专家意见和/或从业者经验。小型回顾性研究试图为铂再激发的实用性提供指导，但它们受到患者特征可变和样本量小的限制。在患者人口统计学不断变化、更好地了解子宫内膜癌驱动因素以及最近批准的免疫检查点抑制剂和乐伐替尼+帕博利珠单抗联合治疗二线患者的背景下，这些回顾性研究难以适用于当代临床实践。本综述的主要重点是提取有关铂双联化疗再激发的可用数据，并强调子宫内膜癌治疗的最新关键进展以及未来的方向。
Endometrial cancer incidence and mortality are rising among all ethnic groups. Carboplatin plus paclitaxel is the established frontline treatment for advanced/recurrent disease; however, subsequent treatment with traditional cytotoxic chemotherapy is challenging. The molecular characterization of endometrial cancer has provided important insights into the biological drivers of carcinogenesis, which has allowed for the development of newer precision immunotherapies and targeted therapies, including pembrolizumab, dostarlimab, and lenvatinib. Until recently, platinum rechallenge was often considered at the time of recurrence, given the lack of other available therapeutic options; however, “platinum sensitivity” in endometrial cancer is subjective and largely based on expert opinion and/or practitioner experience. Small retrospective studies have tried to provide guidance on the utility of platinum rechallenge, but they are limited by variable patient characteristics and small sample sizes. The applicability of these retrospective studies to contemporary clinical practice is difficult in the setting of changing patient demographics, a better understanding of endometrial cancer drivers, and the recent approvals of immune checkpoint inhibitors and the combination of lenvatinib plus pembrolizumab in the second-line setting. The primary focus of this review is to distill the available data regarding platinum-doublet chemotherapy rechallenge and highlight recent pivotal developments in endometrial cancer treatment, as well as future directions.
登录
查看更多内容
影响因子：
45.3
作者：
Dizon, Don S.;Blessing, John A.;Alvarez, Ronald D.
通讯作者：
Alvarez, Ronald D.
影响因子：
11.5
作者：
de Jonge, Marthe M.;Auguste, Aurelie;Bosse, Tjalling
通讯作者：
Bosse, Tjalling
DOI：
10.1158/1078-0432.ccr-20-0953
发表时间：
2020-08-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Fader AN;Roque DM;Siegel E;Buza N;Hui P;Abdelghany O;Chambers S;Secord AA;Havrilesky L;O'Malley DM;Backes FJ;Nevadunsky N;Edraki B;Pikaart D;Lowery W;ElSahwi K;Celano P;Bellone S;Azodi M;Litkouhi B;Ratner E;Silasi DA;Schwartz PE;Santin AD
通讯作者：
Santin AD
影响因子：
8.8
作者：
Evans, T.;Sany, O.;Pearmain, P.;Ganesan, R.;Blann, A.;Sundar, S.
通讯作者：
Sundar, S.
影响因子：
4.7
作者：
Garcia, Agustin A.;Blessing, John A.;Mannel, Robert S.
通讯作者：
Mannel, Robert S.